Αποτελέσματα Αναζήτησης
The contact pathway, less involved in hemostasis but more in thrombosis, appears to offer a safer target for new anticoagulants. Inhibition of this pathway is less likely to cause bleeding than drugs affecting multiple coagulation factors or the common pathways.
New oral anticoagulants include direct inhibitors of thrombin, factor Xa and factor IXa. Designed to provide more streamlined anticoagulation than warfarin, these agents can be given without routine coagulation monitoring.
1 Μαρ 2012 · New agents have been a major source of excitement; with numerous studies published in the past 5 years on the 3 leading new oral direct anticoagulants: dabigatran, rivaroxaban, and apixaban. There are also several additional promising drugs in earlier stages of clinical development.
14 Ιουλ 2020 · Clinical evaluation of new anticoagulants often starts in patients undergoing joint replacement surgery because such patients are at high risk of postoperative venous thromboembolism, particularly asymptomatic deep vein thrombosis (DVT), which can be detected on routine venography.
15 Ιουν 2020 · Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for prevention and treatment of several cardiovascular conditions.
4 Μαρ 2020 · Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge is the side...
25 Φεβ 2015 · This review discusses the new anticoagulants such as dabigatran, edoxaban, rivaroxaban, and apixaban, and provides practical and easy-to-use algorithms for application in the clinical routine specially focused on AF prophylaxis.
